Dosimetry of <superscript>177</superscript> Lu-DOTATOC first circle treatment in patients with advanced metastatic neuroendocrine tumors: A pilot study in China. - OpacWWW

Szczegóły
Abstrakt

Tytuł:: Dosimetry of Lu-DOTATOC first circle treatment in patients with advanced metastatic neuroendocrine tumors: A pilot study in China.
Autorzy:: Xu L; Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, 210006, China.
Meng Q; Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, 210006, China.
Yao X; Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, 210006, China.
Yang R; Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, 210006, China.
Zhang P; Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, 210006, China.
Li R; Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, 210006, China.
Wang F; Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, 210006, China. Electronic address: .
Źródło:: Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine [Appl Radiat Isot] 2022 Jan; Vol. 179, pp. 109975. Date of Electronic Publication: 2021 Oct 02.
Typ publikacji:: Journal Article
Język:: English
Imprint Name(s):: Original Publication: Oxford ; New York : Pergamon Press, c1993-
MeSH Terms:: Radiation Dosage*
Neoplasm Metastasis/*radiotherapy
Neuroendocrine Tumors/*radiotherapy
Octreotide/*analogs & derivatives
Organometallic Compounds/*therapeutic use
Radiometry/*methods
Adult ; China ; Female ; Humans ; Male ; Middle Aged ; Neoplasm Metastasis/diagnostic imaging ; Neuroendocrine Tumors/diagnostic imaging ; Neuroendocrine Tumors/pathology ; Octreotide/pharmacokinetics ; Octreotide/therapeutic use ; Organometallic Compounds/pharmacokinetics ; Pilot Projects ; Positron Emission Tomography Computed Tomography ; Reproducibility of Results ; Single Photon Emission Computed Tomography Computed Tomography
Contributed Indexing:: Keywords: (177)Lu-DOTATOC; Dosimetry; Neuroendocrine tumor; PRRT
Substance Nomenclature:: 0 (Organometallic Compounds)
RGO812Q0C8 (edotreotide lutetium LU-177)
RWM8CCW8GP (Octreotide)
Entry Date(s):: Date Created: 20211106 Date Completed: 20220314 Latest Revision: 20220314
Update Code:: 20240105
DOI:: 10.1016/j.apradiso.2021.109975
PMID:: 34741954
: Czasopismo naukowe

Full Text Finder

First cycle dosimetry calculation of 177 Lu-DOTATOC (single activity:1.59-3.49 GBq) was carried out in eight patients with advanced neuroendocrine tumors (NETs) who underwent whole-body planar (0.5, 24, 48, 72 h) and SPECT/CT scans (24 h). Focal uptake of 177 Lu-DOTATOC was found in primary and metastatic tumors. Organs with the highest absorbed doses per injected activity were tumors (1.293 ± 0.862 mGy/MBq) and spleen (0.461 ± 0.408 mGy/MBq), while low absorbed doses were observed in kidneys (0.384 ± 0.112 mGy/MBq) and bone marrow (0.0297 ± 0.0123 mGy/MBq). 177 Lu-DOTATOC is safe, well-tolerated and appropriate in Chinese NETs patients for PRRT.
(Copyright © 2021. Published by Elsevier Ltd.)

Informacja

Dosimetry of 177 Lu-DOTATOC first circle treatment in patients with advanced metastatic neuroendocrine tumors: A pilot study in China.